$QNTA Medolife Rx Schedules Conference Call with Investment Community to Discuss New Updates and Answer Questions
BURBANK, CA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"
, a global integrated biotech company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC QB: QNTA), announced today that it has scheduled a conference call with investors for Thursday, May 12.
Conference Call Topics:
Potential investment infusion;
Further developments on FDA Pre-IND application #150335 for Escozine as a COVID-19 treatment;
Lobbying to the FDA;
Update on Dominican Republic controlled double-blind clinical strategy for Escozine as a COVID-19 treatment;
Mexico importation and distribution of Escozine, and clinical strategy and preparation for a study on Escozine as a COVID-19 treatment;
The Company’s name and stock symbol change status;
Changes to the Company’s executive management and corporate control;
Additional distribution opportunities;
Implementation of new sales and marketing strategies;
Collaborative opportunities with large pharmaceutical companies;
Change in the Company’s independent auditing firm;
Addressing recent concerns from shareholders;
“We look forward to connecting with our shareholders and provide an update to the Company’s many updates,” said Medolife CEO Dr. Arthur Mikaelian. “The Company has faced many challenges in the recent months that we continue to overcome as we strive toward achieving Medolife’s main goals. We sincerely appreciate the support of our shareholders, and I look forward to providing an informative and comprehensive update clarifying Medolife’s many projects and current strategies.”
Dr. Mikaelian will hold a conference call with the investment community on Thursday, May 12, at 5 p.m. Eastern Standard Time. He will present on the Company’s recently achieved milestones, as well as the future positioning of the Company. Additionally, he will take questions from the investment community at the end of the call.
https://finance.yahoo.com/news/medolife-rx-sc...00529.html
BURBANK, CA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"
, a global integrated biotech company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC QB: QNTA), announced today that it has scheduled a conference call with investors for Thursday, May 12. Conference Call Topics:
Potential investment infusion;
Further developments on FDA Pre-IND application #150335 for Escozine as a COVID-19 treatment;
Lobbying to the FDA;
Update on Dominican Republic controlled double-blind clinical strategy for Escozine as a COVID-19 treatment;
Mexico importation and distribution of Escozine, and clinical strategy and preparation for a study on Escozine as a COVID-19 treatment;
The Company’s name and stock symbol change status;
Changes to the Company’s executive management and corporate control;
Additional distribution opportunities;
Implementation of new sales and marketing strategies;
Collaborative opportunities with large pharmaceutical companies;
Change in the Company’s independent auditing firm;
Addressing recent concerns from shareholders;
“We look forward to connecting with our shareholders and provide an update to the Company’s many updates,” said Medolife CEO Dr. Arthur Mikaelian. “The Company has faced many challenges in the recent months that we continue to overcome as we strive toward achieving Medolife’s main goals. We sincerely appreciate the support of our shareholders, and I look forward to providing an informative and comprehensive update clarifying Medolife’s many projects and current strategies.”
Dr. Mikaelian will hold a conference call with the investment community on Thursday, May 12, at 5 p.m. Eastern Standard Time. He will present on the Company’s recently achieved milestones, as well as the future positioning of the Company. Additionally, he will take questions from the investment community at the end of the call.
https://finance.yahoo.com/news/medolife-rx-sc...00529.html
